ripretinib (Qinlock) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

  • Now
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$263.8939 - $350.1954
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.



Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue